Lipid‑Lowering Therapy Recommendations for Patients with Myasthenia Gravis

Statin Use in Myasthenia Gravis

All currently marketed statins (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, rosuvastatin) have comparable myopathy risk in the general population, indicating no single statin is inherently safer for MG patients. 1
Initiate statin therapy at moderate‑intensity doses rather than high‑intensity regimens to minimize overall myopathy risk. (Evidence from a 2013 cardiology review.) 2
If a patient experiences MG worsening on one statin, a trial of a different statin may be successful, but requires close monitoring. (Evidence from a 2013 cardiology review.) 2

Fenofibrate is the fibrate of choice for triglyceride lowering in MG patients, especially when triglycerides are ≥ 500 mg/dL. (Guideline summary, 2026.) 3
When combined with statins, fenofibrate shows ≈15‑fold fewer rhabdomyolysis reports than gemfibrozil (0.58 vs 8.6 cases per million prescriptions). (Guideline summary, 2026.) 3
In the FIELD trial (≈9,795 participants, ~1,000 receiving statin‑fenofibrate), no rhabdomyolysis cases were observed, supporting safety of the combination. (Randomized controlled trial, 2026.) 3
The ACCORD trial demonstrated no statistically significant increase in myositis, rhabdomyolysis, or hepatic transaminase elevations with statin‑fenofibrate versus statin monotherapy. (Randomized controlled trial, 2026.) 3
Gemfibrozil should never be combined with any statin in MG patients because the combination carries a markedly elevated myopathy risk and is considered a relative contraindication. (Guideline summary, 2026.) 3
Recommended combination dosing for patients requiring both agents: atorvastatin 10–40 mg daily plus fenofibrate 160 mg daily, with a preference for moderate‑intensity statin dosing. (Guideline summary, 2026.) 3

Ezetimibe is better tolerated than statins in statin‑intolerant patients, with myopathy rates of 17–32 % versus 62–81 % for statins. (Evidence from a 2013 cardiology review.) 2

Advanced age (> 80 years) and frailty increase baseline risk for statin‑related adverse events. (Guideline summary, 2026.) 3
Chronic renal insufficiency, especially when accompanied by diabetes, heightens the risk of statin complications. (Guideline summary, 2026.) 3
Peri‑operative periods: withholding statins during major surgery is advised to avoid compounding neuromuscular complications in MG patients. (Guideline summary, 2026.) 3

Do not dismiss new muscle symptoms in MG patients as “just statin myalgia”; assess for MG‑specific weakness patterns (oculobulbar predominance, fatigability). (Guideline consensus, not cited.)
Avoid the gemfibrozil‑statin combination under any circumstances due to unacceptable myopathy risk. (Guideline summary, 2026.) 3

Strength of evidence: